https://scholars.lib.ntu.edu.tw/handle/123456789/628837
標題: | LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer | 作者: | Tsuboi, Masahiro Goldman, Jonathan W Wu, Yi-Long Johnson, Melissa L Paz-Ares, Luis CHIH-HSIN YANG Besse, Benjamin Su, Weiji Chao, Bo H Drilon, Alexander |
關鍵字: | RET fusion-positive; RET kinase inhibitor; RET rearrangement; adjuvant therapy; early stage; non-small-cell lung cancer; phase III trial; selpercatinib; stage IB; stage II; stage IIIA; targeted therapy | 公開日期: | 九月-2022 | 出版社: | FUTURE MEDICINE LTD | 卷: | 18 | 期: | 28 | 起(迄)頁: | 3133 | 來源出版物: | Future oncology (London, England) | 摘要: | Selpercatinib, a first-in-class, highly selective and potent central nervous system-active RET kinase inhibitor demonstrated clinically meaningful activity with manageable toxicity in pretreated and treatment-naive advanced/metastatic RET fusion-positive non-small-cell lung cancer (NSCLC). LIBRETTO-432 is a global, randomized, double-blind, phase III trial evaluating selpercatinib versus placebo in stage IB-IIIA, RET fusion-positive NSCLC, previously treated with definitive surgery or radiation; participants must have undergone available anti-cancer therapy (including chemotherapy or durvalumab) or not be suitable for it, per investigator's discretion. The primary end point is investigator-assessed event-free survival (EFS) in the primary analysis population (stage II-IIIA RET fusion-positive NSCLC). Key secondary end points include EFS in the overall population, overall survival, and time to distant disease recurrence in the central nervous system. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628837 | ISSN: | 1479-6694 | DOI: | 10.2217/fon-2022-0656 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。